Trials / Withdrawn
WithdrawnNCT02953496
Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries
A Phase 1 Multi-Center, Dose-Escalation Study of Vonapanitase Administered Percutaneously to the Superficial Femoral or Popliteal Artery in Patients With Peripheral Artery Disease
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Proteon Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The research study is designed to assess the technical feasibility and safety of percutaneous administration of vonapanitase to the superficial femoral or popliteal artery in patients with PAD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vonapanitase | Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance. |
Timeline
- Primary completion
- 2019-04-30
- Completion
- 2019-04-30
- First posted
- 2016-11-02
- Last updated
- 2019-05-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02953496. Inclusion in this directory is not an endorsement.